• Activates the immune system
• Inhibits colon, esophagus, lung and bladder carcinogenesis
• Anti-metastatic effects
• Anti-hepatitis C virus activity
• Prevents excessive inflammation

Immune-Ultra is an exceptional protein formulation based on the latest research. Thanks to its remarkable ability to stimulate the immune system, Immune-Ultraoffers new possibilities to patients suffering from immune dysfunction, infections and more importantly cancer.

Immune-Ultra contains a mixture of whey protein isolate and concentrate to which bovine lactoferrin and alpha-lactalbumin have been added. Immune-Ultra contains 4.8g of lactoferrin and 4.1g of alpha-lactalbumin per serving size. The high lactoferrin content is crucial to the effectiveness of neo-Immune. Numerous studies have documented that lactoferrin is beneficial for the immune system, that it can prevent infections, and that it is an effective anti-cancer agent.

Stimulation of the immune system
Research has clearly demonstrated that lactoferrin can directly stimulate the immune system. Lactoferrin stimulates the production of cytokines and immune cells, increases IL-18 levels (see figure 1), activates natural killer cells and enhances the cytotoxicity of neutrophils and macrophages. In short, lactoferrin helps to mount an effective immune response (see figure 4).

Thanks to its immunostimulating effect, supplemental oral lactoferrin is effective against a broad range of tumors. Initial experimental animal studies showed that bovine lactoferrin significantly inhibits colon, esophagus, lung and bladder carcinogenesis. These encouraging results led researchers to test the efficacy of recombinant human (rh) lactoferrin in cancer patients. In a preliminary trial, it was found that oral lactoferrin had an immunostimulating action at the level of the gut, inducing a systemic anti-cancer effect. Supplementation resulted in a decrease in the rate of tumor growth in 6 out of 7 patients. Tumor growth was reduced from 33.3% before treatment to 9.9% after treatment with lactoferrin for a period of 2 months (see figure 3).

After the results obtained with rh-lactoferrin in this phase I clinical trial, the US Food and Drug Administration granted Fast Track designation to the clinical development of lactoferrin. The Fast Track designation is intended for the combination of a product and a claim that address an unmet medical need. Rh-lactoferrin is currently undergoing phase II clinical trials for the treatment of renal cell carcinoma (RCC). Human and bovine lactoferrin share a similar structure, amino acid sequence and biological activity. Recent research has shown that bovine lactoferrin is in fact a more potent inhibitor of certain human viruses.

AOR Immune Ultra - 1kg

A direct apoptotic effect
Lactoferricin is a peptide fraction that is obtained from the digestion of lactoferrin in the stomach. Lactoferricin induces apoptosis directly in several cancerous cell lines. More specifically, lactoferricin induces apoptosis in human leukemia, lymphoma, breast, colon and ovarian cancer cells. It is thought that this induction results from an effect at the level of the mitochondrion.

Studies in cell lines have also confirmed that alpha-lactalbumin can inhibit the growth of human cancer cells.

Figure 1: Immune activation in the small intestine of mice 24h after seven consecutive daily administrations of bovine lactoferrin (bLF). IFN-g potentiates the antiviral and antitumor effects of the type I interferons. IL-18 enhances NK cell activity - the cells responsible for the destruction of cancer cells.

Figure 2: Inhibition of angiogenesis by bovine lactoferrin (bLF).

Figure 3: Average change in tumor growth rates in cancer patients before and after treatment with human lactoferrin (TLF).

References

Sternhagen LG, Allen JC. Growth rates of a human colon adenocarcinoma cell line are regulated by the milk protein alpha-lactalbumin. Adv Exp Med Biol. 2001;501:115-20.

Tsuda H, Sekine K, Fujita K, Ligo M. Cancer prevention by bovine lactoferrin and underlying mechanisms--a review of experimental and clinical studies.

Biochem Cell Biol. 2002;80(1):131-6.

Hayes TG, Falchook GF, Varadhachary GR, Smith DP, Davis LD, Dhingra HM, Hayes BP, Varadhachary A. Phase I trial of oral talactoferrin alfa in refractory solid tumors. Invest New Drugs. 2006 May;24(3):233-40.

Levay PF, Viljoen M. Lactoferrin: a general review. Haematologica. 1995 May-Jun;80(3):252-67.

Bounous G. Whey protein concentrate (WPC) and glutathione modulation in cancer treatment. Anticancer Res. 2000 Nov-Dec;20(6C):4785-92.

Brock JH. The physiology of lactoferrin. Biochem Cell Biol. 2002;80(1):1-6.

Shimamura M, Yamamoto Y, Ashino H, Oikawa T, Hazato T, Tsuda H, Iigo M. Bovine lactoferrin inhibits tumor-induced angiogenesis. Int J Cancer. 2004 Aug 10;111(1):111-6.

Tsuda H, Sekine K, Takasuka N, Toriyama-Baba H, Iigo M. Prevention of colon carcinogenesis and carcinoma metastasis by orally administered bovine lactoferrin in animals. Biofactors. 2000;12(1-4):83-8.

Mistry N, Drobni P, Naslund J, Sunkari VG, Jenssen H, Evander M. The anti-papillomavirus activity of human and bovine lactoferricin. Antiviral Res. 2007 Apr 20

Parodi PW. A Role for Milk Proteins and their Peptides in Cancer Prevention. Curr Pharm Des. 2007;13(8):813-28.

Copyright © 2005, Advanced Orthomolecular Research